Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation

MicroRNA-181a knockdown protects HepaRG cells from Dichlorvos-induced oxidative stress and apoptosis

The present study was designed to assess the molecular mechanism of Dichlorvos (DDVP)-induced hepatic cell toxicity in vitro using HepaRG cells. The cytotoxicity was determined by cell viability, apoptosis portion, and reactive oxygenspecies (ROS) generation. The results indicated that DDVP treatment significantly inhibited cell growth, induced cell apoptosis and promoted the production of ROS on HepaRG cells. Microarray analysis showed that miR-181a was significantly upregulated in HepaRG cells treated with DDVP. Furthermore, we found that miR-181a downregulation has a remedy effect on DDVP-induced cell toxicity, while miR-181a overexpression augments the DDVP-induced hepatic cell apoptosis and ROS production. Furthermore studies showed that miR-181a directly targeted Bcl-2, and Bcl-2 downregulation inhibited the remedy effect of miR-181a inhibitor on DDVP induced cell toxicity. It is, therefore, concluded that miR-181a knockdown could protect hepatic cells from DDVP induced oxidative stress and apoptosis by targeting bcl-2.

Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis

During chronic liver injury, hepatic stellate cells (HSC) are activated and proliferate, which causes excessive extracellular matrix (ECM) deposition, leading to scar formation and fibrosis. Medicinal plants are gaining popularity as antifibrotic agents, and are often safe, cost-effective, and versatile. This review aims to describe the protective role and mechanisms of medicinal plants in the inhibition of HSC activation and ECM deposition during the pathogenesis of liver fibrosis. A systematic literature review on the anti-fibrotic mechanisms of hepatoprotective plants was performed in PubMed, which yielded articles about twelve relevant plants. Many of these plants act via disruption of the transforming growth factor beta 1 signaling pathway, possibly through reduction in oxidative stress. This reduction could explain the inhibition of HSC activation and reduction in ECM deposition. Medicinal plants could be a source of anti-liver fibrosis compounds.

Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells

Following chronic liver injury, hepatocytes undergo apoptosis leading to activation of hepatic stellate cells (HSC). Consequently, activated HSC proliferate and produce excessive extracellular matrix, responsible for the scar formation. The pandemic trend of obesity, combined with the high incidence of alcohol intake and viral hepatitis infections, highlights the urgent need to find accessible antifibrotic therapies. Treatment strategies should take into account the versatility of its pathogenesis and act on all the cell lines involved to reduce liver fibrosis. Medicinal plants are achieving popularity as antifibrotic agents, supported by their safety, cost-effectiveness, and versatility. This review will describe the role of hepatocytes and HSC in the pathogenesis of liver fibrosis and detail the mechanisms of modulation of apoptosis of both cell lines by twelve known hepatoprotective plants in order to reduce liver fibrosis.

Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies

The response to injury is one of wound healing and fibrogenesis, which ultimately leads to fibrosis. The fibrogenic response to injury is a generalized one across virtually all organ systems. In the liver, the injury response, typically occurring over a prolonged period of time, leads to cirrhosis (although it should be pointed out that not all patients with liver injury develop cirrhosis). The fact that many different diseases result in cirrhosis suggests a common pathogenesis. The study of hepatic fibrogenesis over the past 2 decades has been remarkably active, leading to a considerable understanding of this process. It clearly has been shown that the hepatic stellate cell is a central component in the fibrogenic process. It also has been recognized that other effector cells are important in the fibrogenic process, including resident fibroblasts, bone marrow-derived cells, fibrocytes, and even perhaps cells derived from epithelial cells (ie, through epithelial to mesenchymal transition). A key aspect of the biology of fibrogenesis is that the fibrogenic process is dynamic; thus, even advanced fibrosis (or cirrhosis) is reversible. Together, an understanding of the cellular basis for liver fibrogenesis, along with multiple aspects of the basic pathogenesis of fibrosis, have highlighted many exciting potential therapeutic opportunities. Thus, although the most effective antifibrotic therapy is simply treatment of the underlying disease, in situations in which this is not possible, specific antifibrotic therapy is likely not only to become feasible, but will soon become a reality. This review highlights the mechanisms underlying fibrogenesis that may be translated into future antifibrotic therapies and to review the current state of clinical development.

The Salvia miltiorrhiza monomer IH764-3 induces apoptosis of hepatic stellate cells in vivo in a bile duct ligation-induced model of liver fibrosis

During the process of liver fibrosis, hepatic stellate cells (HSCs) play a critical role in the excessive production of extracellular matrix (ECM). Previous studies have indicated that the monomer IH764-3, one of the major bioactive components of Salvia miltiorrhiza, is able to inhibit HSC proliferation and induce the apoptosis of activated HSCs in vitro. In the current study, we used a rat model of liver fibrosis induced by bile duct ligation (BDL) to investigate the effect of the monomer IH764-3 on the induction of apoptosis in HSCs in vivo. The rat model of liver fibrosis was established by BDL. Immunohistochemical staining of α-smooth muscle actin (α-SMA) was performed to detect HSC activation and proliferation and HSC apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and α-SMA immunohistochemical double staining. In addition, the protein expression levels of focal adhesion kinase (FAK), p-FAK (Tyr397), extracellular signal-regulated kinase (ERK) and p-ERK and the mRNA expression levels of FAK and ERK were measured by western blotting and reverse transcription-polymerase chain reaction (RT-PCR), respectively. The monomer IH764-3 was associated with a significant decrease in intrahepatic fibrogenesis and collagen deposition and attenuated the liver fibrosis induced by BDL. Immunohistochemical staining revealed that the expression of α-SMA in the IH764-3 group was significantly decreased compared with that in the model group (12.92±2.45 vs. 22.65±2.16%, P<0.01). TUNEL and α-SMA immunohistochemical double staining also confirmed that IH764-3 increased the apoptotic rate of the activated HSCs (34.8±4.5 vs. 4.72±0.37%, P<0.01). Moreover, the results revealed that IH764-3 downregulated the expression levels of FAK, p-FAK (Tyr397), ERK and p-ERK in the liver tissue of rats with liver fibrosis. The monomer IH764-3 ameliorates experimental liver fibrosis by inhibiting HSC proliferation and inducing HSC apoptosis, warranting its use as a potential therapeutic agent in the treatment of liver fibrosis.

Current and future anti-fibrotic therapies for chronic liver disease

Chronic injury results in a wound healing response that eventually leads to fibrosis. The response is generalized, with features common among multiple organ systems. In the liver, various different types of injury lead to fibrogenesis, implying a common pathogenesis. Although several specific therapies for patients who have different liver diseases have been successfully developed, including antiviral therapies for those who have hepatitis B and hepatitis C virus infection, specific and effective antifibrotic therapy remains elusive. Over the past 2 decades, great advances in the understanding of fibrosis have been made and multiple mechanisms underlying hepatic fibrogenesis uncovered. Elucidation of these mechanisms has been of fundamental importance in highlighting novel potential therapies. Preclinical studies have indicated several putative therapies that might abrogate fibrogenesis. This article emphasizes mechanisms underlying fibrogenesis and reviews available and future therapeutics.

Bakuchiol-induced caspase-3-dependent apoptosis occurs through c-Jun NH2-terminal kinase-mediated mitochondrial translocation of Bax in rat liver myofibroblasts

Liver fibrosis and cirrhosis may be reversible, possibly through the selective clearance of activated hepatic stellate cells/myofibroblasts by apoptosis. Hepatic stellate cells transdifferentiate into myofibroblast-phenotype cells in culture, a process that recapitulates hepatic stellate cell activation in vivo. Bakuchiol, a prenylated phenolic terpene isolated from the seed of Psoralea corylifolia L. (Leguminosae), reduced activated hepatic stellate cells when treated to rats during liver injury recovery period as demonstrated by alpha-smooth muscle actin immunostaining in rat liver and induced apoptosis in activated hepatic stellate cells/myofibroblasts as demonstrated by DNA fragmentation, activation of caspase-3, release of cytochrome c into the cytoplasm, translocation of Bax into mitochondria, and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP) in vitro. Bakuchiol-induced apoptosis was prevented by z-DEVD-fmk, a specific inhibitor of caspase-3, and z-VAD-fmk, a general caspase inhibitor, suggesting that bakuchiol-induced apoptosis occurs through a caspase-3-dependent pathway in vitro. Bakuchiol treatment stimulated the activation of extracellular signal-regulated kinase 1/2 (ERK), c-Jun NH2-terminal protein kinase (JNK), and p38 mitogen-activated protein kinases (MAPK) in vitro. Pretreatment with SP600125 attenuated the bakuchiol-induced translocation of Bax into mitochondria, cytochrome c release into the cytosol, caspase-3 activation, and PARP cleavage. In contrast, preincubation with SB203580, a p38 MAPK inhibitor, and U0126, an ERK inhibitor, had no effect on bakuchiol-induced cell death and caspase-3 activity. Taken together, these findings indicate that bakuchiol induces caspase-3-dependent apoptosis through the activation of JNK, followed by Bax translocation into mitochondria in rat liver myofibroblasts.

The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis

Liver fibrosis and its end-stage disease cirrhosis are major world health problems arising from chronic injury of the liver by a variety of etiological factors including viruses, alcohol and drug abuse, the metabolic syndrome, autoimmune disease and hereditary disorders of metabolism. Fibrosis is a progressive pathological process in which wound-healing myofibroblasts of the liver respond to injury by promoting replacement of the normal hepatic tissue with a scar-like matrix composed of cross-linked collagen. Until recently it was believed that this process was irreversible. However emerging experimental and clinical evidence is starting to show that even cirrhosis is potentially reversible. Key to this is the discovery that reversion of fibrosis is accompanied by clearance of hepatic stellate cells (HSC) by apoptosis. Furthermore, proof-of-concept studies in rodents have demonstrated that experimental augmentation of HSC apoptosis will promote the resolution of fibrosis. Consequently there is now considerable interest in determining the molecular events that regulate HSC apoptosis and the discovery of drugs that will stimulate HSC apoptosis in a selective manner. This review will consider the regulatory role played by growth factors (e.g. NGF, IGF-1, TGFbeta), death receptor ligands (TRAIL, FAS), components and regulators of extracellular matrix (integrins, collagen, matrix metalloproteinases and their tissue inhibitors) and signal transduction proteins and transcription factors (Rho/Rho kinase, Jun N-terminal Kinase (JNK), IkappaKinase (IKK), NF-kappa B). The potential for known pharmacological agents such as gliotoxin, sulfasalazine, benzodiazepine ligands, curcumin and tanshinone I to induce HSC apoptosis and therefore to be used therapeutically will be explored.

Antifibrotic therapy in chronic liver disease

The response to injury is one of wound healing and, subsequently, fibrosis. This response is generalized, occurring in diverse organ systems. Injury and wounding in the liver ultimately lead to cirrhosis in many patients (although not all patients), and are the result of many different diseases. The fact that various diseases result in cirrhosis suggests a common pathogenesis. Study over the past 2 decades has shed considerable light on the pathogenesis of fibrosis and cirrhosis. A growing body of literature indicates that the hepatic stellate cell is a central component in the fibrogenic process. Stellate cells undergo a transformation during injury that has been termed activation. Activation is complex and multifaceted, but one of its most prominent features is the synthesis of large amounts of extracellular matrix, resulting in deposition of scar or fibrous tissue. The fibrogenic process is dynamic; it is noteworthy that even advanced fibrosis (or cirrhosis) is reversible. The best antifibrotic therapy is treatment of the underlying disease. For example, eradication of hepatitis B or C virus can lead to the reversal of fibrosis. In situations in which treating the underlying process is not possible, specific antifibrotic therapy is desirable. A number of specific antifibrotic therapies have been tried, but have been met with poor or mediocre success. However, elucidation of the mechanisms responsible for fibrogenesis, with particular emphasis on stellate cell biology, has highlighted many putative novel therapies. This article emphasizes mechanisms underlying fibrogenesis, and reviews current antifibrotic therapies as well as potential future approaches.

Inhibitory effect of Danshen-containing serum on proliferation of HSC-T6 cells

AIM: To investigate the inhibitory effect of Danshen-containing serum on the proliferation of HSC-T6 cells and to construct anti-hepatic-fibrosis in vitro system for screening potential herbal drugs.

METHODS: The proliferation status of HSC-T6 cells was evaluated by calculating its growth curve and cloning efficiency. HSC-T6 cells were exposed to different volume fractions of Danshen-containing serum, including 80%, 40%, 20%, 10%, and 5% of original serum, and its inhibitory effect and dose-effect relationship were investigated.

RESULTS: The population doubling time of HSC-T6 was 10.57 hours and its cloning efficiency was 82.4%, which showed that this cell line had good capacity of activity and proliferation for tests. Ranging from 5% to 80% of original concentration, Danshen-containing serum had the dose-dependent inhibitory effect on HSC-T6 cell (analysis by linear regression, coefficient of correlation = 0.9487).

CONCLUSION: The Danshen-containing serum has significantly inhibitory effect on proliferation of HSC-T6 cells in a dose-dependent manner.

Chinese herbs Kangxian ruangan keli inhibits expression of MEK-1 and c-fos in hepatic stellate cell indused by PDGF

AIM: To investigate the effect of Kangxian ruangan keli (KXR) on the expression of MEK-1 and c-fos in hepatic stellate cell (HSC) indused by PDGF.

METHODS: In a serum-free culture system, HSC was treated with a KXR preparation for 24 hours, followed by stimulation with PDGF-BB for 24 hours. Then the cells were incubated again in the medium containing KXR for 3 hours stimulated with PDGF-BB for 5 minutes, and collected. The proliferation of HSC was examined using an MTT assay. MEK-1 was detected with Western blotting and visualized by the enhenced chemiluminescent (ECL) method. The expression of c-fos mRNA was analyzed with in situ hybridization.

RESULTS: The A values for the HSC growing in the media without and with addition of PDGF were 0.170±0.060 and 0.820±0.050, respectively. The PDGF-induced increase was hindered remarkably by KXR preparation in a dose-dependent manner. Reaction values for the systems with 5 g/L and 1.25 g/L of KXR were 0.280±0.030 and 0.430±0.040 respectively, lower significantly than that in the culture free of KXR (0.820±0.050, P < 0.01). In addition, values for MEK-1 in HSC treated with 5 mg/mL and 1.25 mg/mL of KXR were 0.143±0.013, and 0.170±0.007, respectively, being lower than that in the cells treated only with PDGF-BB (0.186±0.010, P < 0.01). The expression level of c-fos mRNA was 0.152±0.010 and 0.163±0.005, respectively, also lower than that of the PDGF group (0.183±0.014, P < 0.01).

CONCLUSION: Within the dose range used in the present study, KXR preparation shows an inhibitory effect on HSC proliferation induced by PDGF. The mechanism of this process may involve interference with Ras-MEK-MAPK singal transduction mediated by PDGF.

Serum from rabbit orally administered cobra venom inhibits growth of implanted hepatocellular carcinoma cells in mice

AIM: To investigate the inhibitory effect of serum preparation from rabbits orally administered cobra venom (SRCV) on implanted hepatocellular carcinoma (HCC) cells in mice.

METHODS: An HCC cell line, HepA, was injected into mice to prepare implanted tumors. The animals (n = 30) were divided randomly into SRCV, 5-fluorouracil (5-FU), and distilled water (control) groups. From the second day after transplantation, 20 mg/kg 5-FU was administered intraperitoneally once a day for 9 d. SRCV (1000 mg/kg) or distilled water (0.2 mL) was given by gastrogavage. Tumor growth inhibition was described by the inhibitory rate (IR). Apoptosis was detected by transmission electron microscopy (TEM), flow cytometry (FCM), and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). Student’s t-test was performed for statistical analysis.

RESULTS: The tumor growth was inhibited markedly by SRCV treatment compared to that in the control group (P < 0.01). The treatment resulted in a significant increase in the apoptotic rate of cancer cells by the factors of 10.5% ± 2.4% and 20.65% ± 3.2% as demonstrated through TUNEL and FCM assays, respectively (P < 0.01). The apoptotic cells were also identified by characteristic ultrastructural features.

CONCLUSION: SRCV can inhibit the growth of implanted HepA cells in mice, and the apoptosis rate appears to elevate during the process.

Gadolinium chloride and salvia miltiorrhiza compound ameliorate reperfusion injury in hepatocellular mitochondria

AIM: To investigate the effect of gadolinium chloride (GaCl₃) and salvia miltiorrhiza compound (SMCo) on ischemia and reperfusion (I/R) injury in hepatocellular mitochondria.

METHODS: Wistar rats were randomly to divided into control group, GaCl₃ group, SMCo group and GaCl₃ + SMCo group (n = 15 each). GaCl₃ (7 mg·kg^-1) was injected into tail vein on d 1 and d 2 in contrast group. SMCo (2 mL·kg^-1) was injected into muscle on d 1 and d 2 in SMCo group. GaCl₃ + SMCo group received both GaCl₃ (iv) and SMCo (im) injection. Control group received saline injection only. On d 3, all the rats were subjected to 2 h ischemia in the middle and left lobes of the liver, followed by reperfusion for 2 h, 6 h and 18 h respectively. The level of serum alanine aminotransferase (ALT) and malondialdehyde (MDA) in hepatocellular mitochondria was measured. Pathological changes in hepatic tissue and in hepatocellular mitochondria were determined with optical microscope and electronic microscope, respectively.

RESULTS: Remarkablly pathohistological and biochemical changes were detected after 6 h of I/R. Compared with control, the level of ALT was decreased in GaCl₃, SMCo and GaCl₃ + SMCo treated groups (1314.0 ± 278.7 vs 809.4 ± 196.1, 716.6 ± 242.8 and 837.2 ± 190.6 IU·L^-1, respectively. P < 0.05). Similarly, the level of MDA was decreased in GaCl₃, SMCo and GaCl₃ + SMCo treated groups (293.1 ± 51.1 vs 190.8 ± 55.5, 214.3 ± 32.9 and 221.0 ± 47.3 nmol·g^-1, respectively, P < 0.05). Accordingly, in control group, swelling, degeneration, focal necrosis, infiltration of leucocyte were found in reperfused tissue under an optical microscope, and mitochondria swelling, rupture and even breakdown were seen under an electronic microscope. These pathohistological and ultrastructural damages caused by I/R were greatly attenuated in GaCl₃, SMCo and GaCl₃ + SMCo treated groups. However, there was no additive effect observed when GaCl₃ and SMCo were used together.

CONCLUSION: Both GaCl₃ and SMCo can alleviate the I/R injury in hepatocellular mitochondria.

Kangxian ruangan keli inhibits hepatic stellate cell proliferation mediated by PDGF

AIM: To investigate the effect of Kangxian ruangan keli (KXR) on hepatic stellate cell (HSC) proliferation mediated by platelet-derived growth factor (PDGF) and the underlying mechanism.

METHODS: In a serum-free culture system, HSCs were treated with a KXR preparation for 24 h, followed by stimulation with PDGF-BB for 24 h. Then the cells were incubated again in the medium containing KXR for 3 h stimulated with PDGF-BB for 5 minutes, and collected. The proliferation of HSC was examined using an MTT assay and flow cytometry. Tyrosine phosphorylation was detected with Western blotting and visualized by the enhenced chemiluminescent (ECL) method.

RESULTS: The OD values for the HSCs growing in the media without and with addition of PDGF were 0.17 ± 0.06 and 0.82 ± 0.05, respectively. The PDGF-induced increase was hindered remarkably by KXR preparation in a dose-dependent manner. The reaction values for the systems with 5 mg/mL, 2.5 mg/mL and 1.25 mg/mL of KXR were 0.28 ± 0.03, 0.37 ± 0.02 and 0.43 ± 0.04, respectively. Moreover, the percentages of S-phase cells in these KXR-containing culture systems were 10.95 ± 1.35, 32.76 ± 1.07 and 43.19 ± 1.09, respectively, all of which were significantly lower than that in the culture free of KXR (68.24 ± 2.72). In addition, the values for tyrosine-phosphorylated protein in HSCs treated with 5 mg/mL and 1.25 mg/mL of KXR were 0.1349 ± 0.0072 and 0.1658 ± 0.0025, respectively, which were smaller than that in the cells treated only with PDGF-BB (0.1813 ± 0.0117).

CONCLUSION: Within the dose range used in the present study, KXR preparation shows an inhibitory effect on HSC proliferation induced by PDGF. The mechanism of this process may involve interference with tyrosine phosphorylation mediated by PDGF.

Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells

AIM: To investigate the characteristics of PPAR gamma ligands induced apoptosis in liver cancer cells.

METHODS: The effects of ligands for each of the PPAR gamma ligands on DNA synthesis and cell viability were examined in BEL-7402 liver cancer cells. Apoptosis was characterized by Hochest33258 staining, DNA fragmentation, TUNEL and ELISA, and cell cycle kinetics by FACS. Modulation of apoptosis related caspases expression by PPAR gamma ligands was examined by Western blot.

RESULTS: PPARgamma ligands, 15-deoxy-^{12, 14}-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of BEL-7402 cells. Both 15d-PGJ2 and TGZ induced BEL-7402 cell death in a dose dependent manner, which was associated with an increase in fragmented DNA and TUNEL-positive cells. At concentrations of 10 and 30 µM, 15d-PGJ₂ or troglitazone increased the proportion of cells with G₀/G₁ phase DNA content and decreased those with S phase DNA content. There was no significant change in the proportion of cells with G₂/M DNA content. The activities of Caspases-3, -6, -7 and -9 were increased by 15d-PGJ2 and TGZ treatment, while the activity of Caspase 8 had not significantly changed.

CONCLUSION: The present results suggest the potential usefulness of PPAR gamma ligands for chemoprevention and treatment of liver cancers.

Effect of Activin on extracelluar matrix secretion in isolated rat hepatic stellate cell

AIM

To investigate the effect of activin A on the extracelluar matrix secretion of rat hepatic stellate cell.

METHODS

Hepatic stellate cells were isolated and purified from normal male Sprague-Dawley rat liver by a combination of pronase-collagenase perfusion and density gradient centrifugation. Passaged hepatic stellate cells were divided randomly into eight groups: control group(A group), ACTA 1 μg/L group (B group), ACTA 10 μg/L group(C group), ACTA 100 μg/L group (D group), TGF β₁ 10 μg/L group(E group), TGF β₁ 10 μg/L plus ACTA 1 μg/L group(F group), TGF β₁ 10 μg/L plus ACTA 10 μg/L group(G group), TGF β₁ 10 μg/L plus ACTA 100 μg/L group(H group). 24 h after incubation secretion of procollagen Ⅲ, collagen Ⅳ and mRNA of collagen Ⅲ in hepatic stellate cells were detected by radioimmunoassays and semi-quantitative RT-PCR method respectively.

RESULTS

Extracellular matrix secretion in passaged hepatic stellate cells was enhanced by activin A according to its concentration, the capacity of extracellular matrix secretion by 100 μg/L activin A was equal to that of 10 μg/L TGF β₁, extracellular matrix secretion and type Ⅲ collagen mRNA expression in passaged hepatic stellate cells was enhanced by activin A and TGFβ₁ in a synergistic manner.

CONCLUSION

Activin A may contribute to hepatic fibrogenesis.

Effects of hepatocyte growth factor on fibrosis and hepatic expression of MMP-1 andTIMP-1

AIM: To investigate the effect of hepatocyte growth factor (HGF) on severity of liver fibrosis and hepatic expressions of MMP-1, TIMP-1 and to explore the mechanism of HGF in preventing liver fibrosis in rats.

METHODS: Eighty male Wistar rats were randomly divided into normal control group (Group A, 16 rats), liver fibrosis model group (Group B, 54 rats) and HGF therapy group (Group C, 10 rats). The liver fibrosis model was induced by administration CCl₄ intraperitoneally. Rats in Group C had been administered HGF for six weeks and were sacrificed afterwards. Eight rats from each of group A and B were randomly sacrificed on week 6 simultaneously as that in group C. The remaining rats in-group B were randomly further subdivided into liver fibrosis model group (Group D, 12 rats) and HGF therapy group (Group E, 10 rats), HGF was administered to rats in group E on week. 7.All rats in group D and E were sacrificed on week 10.Liver function and levels of serum hyaluronic acid (HA), mucin (LN), collegen type IV (CIV), procollagen III (PCIII) were tested; the expression of MMP-1 and TIMP-1 were determined by immunohistochemical staining and analyzed by computer.

RESULTS: Compared with Group B, the serum levels of ALT, AST, HA, LN, CIV, PCIII in Group C were significantly reduced (P < 0.01), MMP-1 activity was slightly increased (0.25 ± 0.02, vs 0.22 ± 0.05, P < 0.05), TIMP-1 activity was markedly reduced (0.34 ± 0.05, vs 0.45 ± 005, P < 0.01). TIMP-1 activity in Group E (0.31 ± 0.07) was also markedly reduced in comparison with Group D (0.42 ± 0.06) (P < 0.01).

CONCLUSIONS: HGF has obvious effect in preventing development of liver fibrosis; it might facilitate degradation of hepatic fibrosic tissue via increasing the MMP-1 activity and or inhibiting TIMP-1 activity.

Effects of Chinese Jianpi herbs on cell apoptosis and related gene expression in human gastric cancer grafted onto nude mice

AIM: To explore the mechanism of the Sijunzi decoction and another Chinese herbal recipe (SRRS) based mainly on the Sijunzi decoction in treatment of gastric cancer.

METHODS: A human gastric adenocarcinoma cell line SGC-7901 grafted onto nude mouse was used as the animal model. The mice were divided into 3 groups, one control and the two representative experimental conditions. Animals in the two experimental groups received either Sijunzi decoction or SRRS over a 40-day period starting at 1st day after grafting. Control animals received saline on an identical schedule. Animals were killed 41 d after being grafted. The effect of therapy was assessed by two ways: (1) tumor size was periodically measured during the life of the animals; (2) tumor weight was determined by a electron balance immediately after the animals killed. For detection of apoptotic cells, apoptotic indices (AI) were examined by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate fluorescence nick end labeling (TUNEL) method. Morphological alterations were observed with electron microscopy. S-P immunohistochemical method was used to detect the expression of Ki-67 in xenografts. Expression of bcl-2 and p53 was semiquantitatively detected using a reverse transcriptase-polymerase chain reaction (RT-PCR) technique.

RESULTS: When compared with controls, tumor growth (size and weight) was significantly inhibited by treatment with the Sijunzi decoction (P < 0.05) or SRRS (P < 0.01). The tumor inhibitory rate in the Sijunzi decoction group was 34.33% and SRRS group 46.53%. AI of human gastric cancer xenografts in nude mice was significantly increased to 16.24% ± 3.21% using TUNEL method and 11.38% ± 6.46% by FACScan in the Sijunzi decoction group compared with the controls (TUNEL: 2.63% ± 1.03%, P < 0.01; FACScan: 7.15% ± 1.32%, P < 0.05). SRRS group was also found a significantly increased AI by using TUNEL method and flow cytometry analysis compared with the controls (TUNEL: 13.18% ± 3.05%, P < 0.05; FACScan: 11.58% ± 5.71% (P < 0.05). Under electron microscope, cell shrinkage, nuclear chromatin condensation, formation of membrane blebs and apoptotic bodies were frequently observed in Sijunzi decoction group and SRRS group. The average labeling index (LI) for Ki-67 in SRRS group was significantly decreased to 8.43% ± 2.22% compared with the control group (10.37% ± 4.91%) (P < 0.05). The average labeling index for Ki-67 in sijunzi decoction group was 7.95% ± 2.54% which was lower than that of the control group, but showed no significance (P = 0.07). The expression level of p53 mRNA was lower in both Sijunzi decoction group and SRRS group than that in control group (P < 0.05; P < 0.01). The expression of bcl-2 mRNA was also decreased in SRRS group compared with the control (P < 0.01).

CONCLUSION: The inhibition of gastric cancer cell growth in vivo by Chinese Jianpi herbs and SRRS is related to induction of the cell apoptosis which may be involved in aberrant expression of p53 and bcl-2 genes.

Apoptosis of hepatoma cells SMMC-7721 induced by Ginkgo biloba seed polysaccharide

AIM: To study the apoptosis of hepatoma cells SMMC-7721 induced by polysaccharide isolated from Ginkgo biloba seed.

METHODS: Ginkgo biloba seed polysaccharide (GBSP) was isolated by ethanol fractionation of Ginkgo biloba seed and purified by Sephadex G-200 chromatography. The purity of GBSP was verified by reaction with iodine-potassium iodide and ninhydrin and confirmed by UV spectrophotometer, cellulose acetate membrane electrophoresis and Sepharose 4B gel filtration chromatography. The Scanning Electron Microscope (SEM) and Flow Cytometry (FCM) were used to examine the SMMC-7721 cells with and without GBSP treatment at 500 mg/mL for 36 h.

RESULTS: GBSP product obtained was of high purity with the average molecular weight of 1.86 × 10⁵. Quantitative analysis of SMMC-7721 cells in vitro with FCM showed that the percentages of G2-M cells without and with GBSP treatment were 17.01% ± 1.28% and 11.77% ± 1.50% (P < 0.05), the debris ratio of the cells were 0.46% ± 0.12% and 0.06% ± 0.06% (P < 0.01), and the apoptosis ratio of cells was 3.84% ± 0.55% and 9.13% ± 1.48% (P < 0.01) respectively. Following GBSP treatment, microvilli of SMMC-7721 cells appeared thinner and the number of spherical cells increased markedly. Most significantly, the apoptosis bodies were formed on and around the spherical cells treated with GBSP.

CONCLUSION: GBSP could potentially induce the apoptosis of SMMC-7721 cells.